Nektar Therapeutics (NKTR): Price and Financial Metrics

Nektar Therapeutics (NKTR)

Today's Latest Price: $17.27 USD

0.80 (4.86%)

Updated Dec 2 4:00pm

Add NKTR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

NKTR Stock Summary

  • Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; merely 9.22% of US stocks have a lower such ratio.
  • NKTR's price/sales ratio is 18.09; that's higher than the P/S ratio of 90.81% of US stocks.
  • With a year-over-year growth in debt of -61.66%, Nektar Therapeutics's debt growth rate surpasses only 4.65% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Nektar Therapeutics, a group of peers worth examining would be NERV, AGIO, ASMB, PRQR, and CLLS.
  • Visit NKTR's SEC page to see the company's official filings. To visit the company's web site, go to

NKTR Stock Price Chart Interactive Chart >

Price chart for NKTR

NKTR Price/Volume Stats

Current price $17.27 52-week high $28.60
Prev. close $16.47 52-week low $13.63
Day low $16.50 Volume 938,986
Day high $17.55 Avg. volume 1,363,094
50-day MA $17.01 Dividend yield N/A
200-day MA $19.69 Market Cap 3.10B

Nektar Therapeutics (NKTR) Company Bio

Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.

NKTR Latest News Stream

Event/Time News Detail
Loading, please wait...

NKTR Latest Social Stream

Loading social stream, please wait...

View Full NKTR Social Stream

Latest NKTR News From Around the Web

Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.

Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Hedge Funds Aren’t Impressed By Nektar Therapeutics (NKTR)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 24, 2020

Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT

Q1 2020 Nektar Therapeutics Earnings Call

Yahoo | June 15, 2020

Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | June 6, 2020

Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)

Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).

Yahoo | June 4, 2020

Read More 'NKTR' Stories Here

NKTR Price Returns

1-mo 7.13%
3-mo -9.82%
6-mo -22.45%
1-year -11.23%
3-year -67.62%
5-year 8.75%
YTD -19.99%
2019 -34.33%
2018 -44.96%
2017 386.72%
2016 -27.18%
2015 8.71%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7987 seconds.